TD Cowen analyst Brendan Smith raised the firm’s price target on Halozyme to $65 from $59 and keeps a Buy rating on the shares. The firm said its Q2 EPS beat was driven by higher-than-expected collab revenues and ENHANZE API sales.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
Questions or Comments about the article? Write to editor@tipranks.com